placebo + letrozole

This is a combination therapy consisting of letrozole, an oral nonsteroidal aromatase inhibitor, and a placebo. Letrozole works by inhibiting the aromatase enzyme, thereby reducing estrogen production in postmenopausal women. This reduction in estrogen slows or stops the growth of hormone receptor-positive breast cancer cells that require estrogen to proliferate. The addition of a placebo serves as a control arm in clinical trials to assess the efficacy and safety of other drug combinations compared to letrozole alone. Placebo + letrozole is not itself an active therapeutic regimen but represents the comparator (control) group in randomized controlled trials evaluating new agents added to standard endocrine therapy with letrozole[1][2][3][4][5].

Other names

placebo plus letrozoleletrozole + placebo